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The mitogen-activated protein kinase (MAPK) pathway is known to play a key role in the
initiation and maintenance of many tumors as well as normal development. This often
occurs through mutation of the genes encoding RAS and RAF proteins which are involved
in signal transduction in this pathway. BRAF is one of three RAF kinases which act as down-
stream effectors of growth factor signaling leading to cell cycle progression, proliferation,
and survival. Initially reported as a point mutation (V600E ) in the majority of metastatic
melanomas, other alterations in the BRAF gene have now been reported in a variety of
human cancers including papillary thyroid cancer, colon carcinomas, hairy cell leukemia,
and more recently in gliomas.The identification of oncogenic mutations in the BRAF gene
have led to a revolution in the treatment of metastatic melanoma using targeted molecular
therapies that affect the MAPK pathway either directly through BRAF inhibition or down-
stream through inhibition of MEK. This review describes the molecular biology of BRAF in
the context of pediatric low-grade gliomas, the role of BRAF as a diagnostic marker, the
prognostic implications of BRAF, and evidence for therapeutic targeting of BRAF.
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INTRODUCTION
Pediatric low-grade gliomas (LGGs) represent the most common
central nervous system (CNS) tumors of childhood, with pilocytic
astrocytomas (PAs) being the most prevalent, accounting for 17%
of brain and spinal neoplasms in children age 0–14 years (1, 2)
(see Table 1). For the purposes of this review, the term LGGs is
used to describe a heterogeneous group of tumors including both
WHO grade I and II neoplasms (see Table 1) (3). The incidence
varies from 0.26 to 1.79/100,000 depending on the histology and
geographical region, with an overall higher incidence in males (1).
Survival is variable with a 5-year overall survival in PAs being
reported as high as 100%, compared to 45% in diffuse fibrillary
astrocytoma (DA) (1, 4). PAs are relatively benign slow growing
tumors occurring most commonly within the cerebellum, but may
also arise along the optic tract, in the hypothalamus and brain stem
where they are difficult to fully resect (5). Complete resection has
been reported in 94% of cerebellar PAs compared with only 3.2%
of hypothalamic and chiasmatic tumors, with an overall tumor
recurrence rate of 19% for PAs (6, 7). PAs of the optic tract are
common in the hereditary syndrome neurofibromatosis type 1 and
are commonly associated with defect in the NF1 gene (8). NF1 loss
Abbreviations: A, grade II astrocytoma; AA, anaplastic astrocytoma; CNS, cen-
tral nervous system; DA, diffuse fibrillary astrocytoma; GBM, glioblastoma mul-
tiforme; GG, ganglioglioma; HGG, high-grade glioma; LGG, low-grade glioma;
MAPK, mitogen-activated protein kinase; ODG, oligodendroglioma; PA, pilocytic
astrocytoma; PFS, progression-free survival; PMA, pilomyxoid astrocytoma; PXA,
pleomorphic xanthoastrocytoma; SGCA, subependymal giant cell astrocytoma.
may activate the mitogen-activated protein kinase (MAPK) path-
way through RAS, which in turn may activate BRAF and the PI3K
pathway (Figure 1) (8–10). DAs have been reported to represent
approximately 3% of pediatric gliomas, although they more com-
monly occur in adults (11). Within the pediatric population, the
higher grade gliomas, anaplastic astrocytoma (AA), and glioblas-
toma multiforme (GBM) account for approximately 5 and 6.5%
of pediatric gliomas, respectively (11).
MOLECULAR BIOLOGY OF BRAF
BRAF fusion
Until recently, the molecular biology of pediatric LGGs was rela-
tively unknown (see Figure 1 and Table 2). The genetic aberrations
commonly seen in adult gliomas including p53, PTEN, CDK4,
and p16 have not been identified in low-grade pediatric gliomas
suggesting that they may be genetically distinct (23).
In 2008, several papers identified a genetic defect in the BRAF
gene thought to be responsible for constitutive activation of the
MAPK pathway and thus development of PAs in children (15, 24,
25). Jones at al. described a tandem duplication at 7q34 resulting
in fusion of the previously uncharacterized gene KIAA1549 and
the BRAF gene to create a novel fusion oncogene in approximately
66% of PAs (15). Other less common fusion variants included exon
15:exon 9, exon 16:exon 11, exon 16:exon 10, exon 15:exon11, exon
17:exon 10, and exon 18:exon 10 (see Table 2) (9, 15, 26, 27). All
fusions were found to have constitutive BRAF kinase activity and
transforming ability in NIH3T3 cell lines (15). The constitutive
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Table 1 | Histological subgroups of low-grade and high-grade gliomas demonstrating in which tumors the BRAF gene fusion has been
identified.
Histological subgroup WHO
grade
KIAA1549:BRAF
fusion
described
Average%
fusion
positive
Other RAF
fusion described
BRAFV600E
described
Average%
BRAFV600E
positive
Reference
Pilocytic astrocytoma I Yes 77.2 FAM131B:BRAF,
SRGAP3:RAF1,
QK1:RAF1
Yes 6.2 (9, 12–19)
Pilomyxoid astrocytoma II Yes 62.5 Yes 5.0 (9, 13, 14, 19, 20)
Diffuse fibrillary astrocytoma II Yes 3.0 FAM131B:BRAF Yes 8.1 (13, 14, 17–19)
Anaplastic astrocytoma III No 0 Yes 15.9 (15, 17, 18, 21)
Glioblastoma multiforme IV No 0 Yes 9.4 (15, 17, 18, 21)
Pleomorphic xanthoastrocytoma II Yes 55.6 Yes 50.8 (13, 14, 17–19)
Ganglioglioma I/II Yes 25.3 BRAF:MACF,
FXR1:BRAF
Yes 20.7 (9, 14, 17–19)
Dysembryoplastic neuroepithelial
tumor
I No 0 No 0 (9, 14, 18)
Desmoplastic infantile
astrocytoma/glioma
II No 0 FXR1:BRAF Yes 8.5 (18, 22)
kinase activity of KIAA1549:BRAF fusion oncoprotein is due to
the loss of the BRAF N-terminal auto-inhibitory domain which
usually regulates BRAF activity (15, 28). Lin et al. demonstrated
that the KIAA1549:BRAF fusion is transcribed from the KIAA1549
gene promoter and thus is expressed at higher levels than wild-
type BRAF, so the fusion oncoprotein is not only constitutively
active but also over expressed giving two mechanisms of aber-
rant activity (27). Investigation into the effects of the oncogenic
fusion protein formed by KIAA1549 and BRAF has revealed that
the constitutive activation regulates neuroglial cell growth in a cell-
type-specific manner causing proliferation of neural stem cells but
not mature astrocytes (29). In certain studies, the KIAA1549:BRAF
fusion gene was also found to function through MEK-dependent
activation of both MAPK and mTOR pathways and the injec-
tion of neural stem cells containing the fusion were sufficient
to induce glioma-like lesions in mice (29). Whereas other stud-
ies report that expression of the KIAA1549:BRAF fusion protein
alone is not sufficient for gliomagenesis and instead results in
senescence (29–31). More recently, several novel gene fusions
have been discovered which may account for MAPK activation
in PAs which do not harbor the KIAA1549:BRAF fusion vari-
ants, summarized in Table 2 (12, 13, 16, 26). A further novel
mutation at codon 209 in the GNAQ gene has been described
in a single case of PA (32). GNAQ encodes a Gα subunit of the
guanine nucleotide-binding protein receptor involved in signaling
upstream of RAS (33). Mutations in the GNAQ gene are thought to
lead to constitutive activation of the MAPK pathway, independent
of BRAF (33).
BRAF V600E mutation
Characterization of mutant proteins has revealed a mutation
hotspot resulting in a valine to glutamate substitution at position
600, often referred to as BRAF V600E in a range of tumor
types (20, 35–39). The BRAF protein and its close relation RAF1
(CRAF) are usually subject to auto-regulation through differ-
ent N-terminal auto-inhibitory domains (28). The oncogenic
V600E mutation lies within the activation segment disrupting
the auto-inhibitory mechanism and converting BRAF into its
active form thus allowing constitutive activation of the MAPK
pathway (40). Gronych et al. demonstrated that overexpres-
sion of the mutant BRAF V600E kinase domain alone induced
tumor formation with clinical and histological features of PAs
whereas the full length V600E mutant protein which still con-
tained the autoregulatory domain did not give rise to tumors
(31). In inkk4a/ARF-deficient mice, the full length BRAF V600E
could induce tumorigenesis but these more closely resembled
high-grade astrocytomas (31). Lyustikman et al. demonstrated
a causal relationship between constitutive activation of RAF1,
and thus the downstream MAPK signaling pathway, and glioma
formation in mice (30). Activation of RAF1 alone induced hyper-
plastic lesions in Ntv-a mice, yet such lesions did not progress
without concomitant loss of ARF (see Figure 1). With loss
of ARF and the RAF1 mutation, mice developed lesions sim-
ilar to glioblastoma, yet without ARF loss, small hyperplastic
lesions developed which may represent tumors more similar to
PAs (30). Huillard et al. reported that the presence of BRAF
V600E alone was insufficient for gliomagenesis and a concomi-
tant homozygous deletion of CDKN2A (which encodes P14ARF
and P16INK4A) was required for the development of astrocytomas
from neural progenitor cells (Figure 1) (41). It was demonstrated
that expression of BRAFV600E may cause transformation when
combined with loss of CDKN2A in human neural progenitor cells
and the resultant tumors displayed the histology of malignant
astrocytomas (41).
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FIGURE 1 | Schematic diagram detailing the currently identified aberrations in the MAPK pathway genes thought to be responsible for the
development of pilocytic astrocytomas.
Outwith the glioma biology field, it has been proposed that
the BRAF V600E mutation may be responsible for the induc-
tion of growth arrest and senescence in melanocytic naevi,
in a process termed “oncogene-induced senescence” whereby
melanocytic naevi can remain in growth arrest for a lifetime
(42). Oncogene-induced senescence has been described when
BRAF V600E mutation was introduced with a lentiviral vector
into human neurospheres derived from the cerebral cortex of
first trimester human fetal autopsy specimens (43). Neurosphere
cells initially underwent transformation, subsequently followed
by senescence with expression of senescence-associated markers
(44). Interestingly, Jacob et al. have described that the majority
of PAs are senescent and that this effect is triggered through the
p16ink4a pathway following aberrant MAPK activity (45). More-
over, Hawkins et al. overexpressed BRAF in hTERT immortalized
human astrocytes and found that this caused growth arrest and
senescence with associated DNA damage (32).
BRAF AS A DIAGNOSTIC MARKER
BRAF fusion
The KIAA1549:BRAF fusion has been reported in a range of PAs
(59–90%) and so it is increasingly used as a diagnostic marker for
PAs, where neuropathological distinction from malignant glioma
can be difficult (46, 47). The literature is divided on the incidence
of BRAF fusions in other pediatric LGGs which has implications
for testing of these entities (9, 14, 22, 43, 46, 47). A few studies have
shown a lack of BRAF fusions in ganglioglioma (GG), desmoplas-
tic infantile GG/astrocytoma, dysembryoplastic neuroepithelial
tumor, pilomyxoid astrocytoma (PMA), and pleomorphic xan-
thoastrocytoma (PXA) (9, 22, 43, 46, 47). By contrast, Horbinski
et al. describe BRAF rearrangements in up to 15% of non-pilocytic
LGGs including GG, PMA, and PXA, but not DAs (14). In a
larger study by Hawkins et al. of pediatric low-grade astrocytomas
including 105 PAs, 6 PMAs, 71 diffuse astrocytomas, and 4 unspec-
ified low-grade astrocytomas,BRAF fusions were described in 62%
of PAs, 67% of PMAs, 37% of diffuse astrocytomas, and 50% of
unspecified low-grade astrocytomas.
Cin et al. screened 125 primary PAs for the known
KIAA1549:BRAF fusion, the SRGAP3:RAF1 fusion, and also
described a novel fusion between the otherwise uncharacterized
gene product FAM131B and BRAF (12). In this study, fusions were
identified in 82% of cerebellar PAs and 57% of non-cerebellar PAs,
and a further 4.8% of tumors contained the BRAF V600E mutation
(12). Cykowski et al. report the use of the KIAA1549:BRAF fusion
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Table 2 | Gene fusions involving members of the MAPK pathway including BRAF and in which low-grade gliomas the fusions have been
identified.
MAPK
pathway
gene
Gene fusion Exon variant Tumors fusion
is present in
WHO grade Reference
BRAF KIAA1549:BRAF exons 16:9, exons 15:9,
exons 16:11
PA, PMA, PXA, GG,
SGCA, DA (A and ODG)
I, II (9, 13, 15, 24, 32, 34)
BRAF KIAA1549:BRAF exons 15:8 PA I (12)
BRAF KIAA1549:BRAF exons 16:10 PA I (26)
BRAF KIAA1549:BRAF exons 15:11, exons 17:10 PA, LGG I, II (27)
BRAF KIAA1549:BRAF exons 18:10 PA I (9, 13)
BRAF KIAA1549:BRAF exons 19:9 PA I (13)
BRAF FAM131B:BRAF exons 2:9, exons 3:9,
exons 2:10
PA I (12)
BRAF FXR1:BRAF Not reported DA II (19)
BRAF BRAF:MACF Not reported GG II (19)
RAF1 SRGAP3:RAF1 exons 12:10 PA I (16)
RAF1 SRGAP3:RAF1 exons 12:7, exons 11:9 PA I (12)
RAF1 SRGAP3:RAF1 exons 11:8 PA I (13)
RAF1 QK1:RAF1 Not reported PA I (19)
PA, pilocytic astrocytoma; PMA, pilomyxoid astrocytoma; PXA, pleomorphic astrocytoma; DA, diffuse fibrillary astrocytoma; A, grade II astrocytoma not further
specified; GG, ganglioglioma; SGCA, subependymal giant cell astrocytoma; ODG, oligodendroglioma; LGG, low-grade gliomas not further specified. A and ODG were
found to have the KIAA1549:BRAF fusion in 6 of 118 cases and were thought to be misdiagnosed PA as they all followed a particularly benign clinical course (15).
and TP53 to distinguish PAs with atypical features from the highly
malignant glioblastoma (48). Korshunov et al. describe the use
of the KIAA1549:BRAF fusion to distinguish PAs from R132H
IDH1 mutation positive diffuse astrocytoma counterparts with
high specificity, with a consistent lack of R132H IDH1 mutation
positivity in PAs (49).
BRAF V600E mutation
In a large cohort study of CNS tumors ranging from grade I
to grade IV cancers, BRAF V600E mutation occurred most fre-
quently in 66.7% of PXAs, but was also found at lower levels in
PAs, GGs, and malignant gliomas (17). In another cohort study
of over 1,300 CNS tumors, 66.7% of PXAs, 18% of GGs, and
9% of extra-cerebellar PAs harbored the BRAF V600E mutation
(4). Further mutations have been found in the BRAF gene in
gliomas including a 3bp insertion at codon 598 which mimics
the V600E mutation (16). Further findings indicate that aberra-
tions of MYB and MYBL1 may help distinguish LGGs from PAs
as these aberrations were found in 68% of diffuse astrocytomas
but 0% pilocytic tumors (42). The BRAF V600E mutant and the
KIAA1549:BRAF fusion are generally mutually exclusive with only
a few cases reported with both the fusion and the V600E mutation
(12, 14, 32).
In summary, although currently assessment of the BRAF fusion
is of most diagnostic use in posterior fossa PAs, and the BRAF
V600E mutation is more prevalent in PXAs, both of these alter-
ations have been described to varying degrees in other pediatric
LGGs including DA.
PROGNOSTIC IMPLICATIONS OF BRAF STATUS
Although there is much debate over the association of the fusion
status with outcome, it remains generally accepted that the patient
age, location of the tumor, and extent of resection are the most
important prognostic indicators (6, 7, 14, 50). However, the pres-
ence of the KIAA1549:BRAF fusion positive compared to fusion
negative pediatric LGGs has been associated with improved out-
come in two studies (14, 32) and reported to have no effect on
outcome in four (6, 15, 27, 34). For example, in one of the posi-
tive studies, the KIAA1549:BRAF fusion was associated with better
clinical outcome in the large cohort by Hawkins et al. of pediatric
low-grade astrocytomas including PAs, PMAs, and diffuse astrocy-
tomas (32). In this study, all LGGs included were extra-cerebellar,
incompletely resected (less than 75% resection), and followed up
for more than 1 year (32). The overall findings were that the 5-year
progression-free survival (PFS) was 61% in BRAF fusion positive
tumors compared to 18% in fusion negative tumors (with PFS
defined as greater than 25% increase in tumor volume on con-
secutive MRI scans) (32). Moreover, multivariate analysis revealed
that BRAF fusion was an independent prognostic factor in incom-
pletely resected LGGs (32). Significantly, all fusion negative PA
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patients under the age of 18 months experienced progression of
their tumors within 8 years of diagnosis, and three of five patients
in this group died within the study period of 16 years (32). In
the second positive study, Horbinski et al. also report the pres-
ence of BRAF rearrangements as a positive prognostic marker in
a cohort of LGGs including PAs, GGs, PMAs, PXAs, diffuse astro-
cytomas, oligodendrogliomas (ODGs), subependymal giant cell
astrocytomas (SGCAs), dysembryoplastic neuroepithelial tumors,
and LGGs not otherwise specified (14). BRAF rearrangement was
found to be associated with longer PFS and decreased risk of death,
only one fusion positive patient died within the 20-year follow-up
period (14).
However, it is possible that the BRAF fusion is more a diagnos-
tic marker of the PA which has an inherent better prognosis, as
other studies of PA demonstrate no survival advantage in BRAF
fusion positive cases compared with negative cases (6, 15, 27, 51).
In a small cohort of PAs, the presence of the BRAF V600E mutation
has been reported to be significantly associated with both diffusely
infiltrating architecture and increased risk of progression in LGGs
(14, 52).
The association with location is less controversial with mount-
ing evidence that the BRAF V600E mutation is more common in
supratentorial PAs and the KIAA1549:BRAF fusion being more
common in posterior fossa PAs (14, 33, 34, 53, 54). However,
further evidence from Hawkins et al. looking specifically at supra-
tentorial LGGs found that midline tumors which are usually unre-
sectable were more likely to harbor the KIAA1549:BRAF fusion
(65% cases) compared to only 11% of lobar tumors which were
found to be BRAF fusion positive (32). In this study, it was also
found that BRAF fusion positive tumors had better 5-year PFS
irrespective of tumor histotype or location with 5-year PFS of
65% in fusion positive PAs compared to 17% for fusion negative
tumors (32).
THERAPEUTIC TARGETING OF BRAF AND MAPK PATHWAY
BRAF and MAPK inhibitors in cell lines and animal models
Non-central nervous system cell lines and xenografts. Therapeu-
tic manipulation of the BRAF and MAPK pathway has been exten-
sively investigated in many tumor types (see Figure 1 and Table 3).
For example, sorafenib is a potent RAF1 inhibitor with action
against BRAF, PDGFRβ, and VEGFR-3 (55). Sorafenib has been
shown to act against both wild-type and BRAF V600E mutant cell
lines and colon, breast, and non-small cell lung cancer xenograft
models (55, 56). Inhibition of tumor growth in these models was
not associated with any apparent toxicities and appeared to be
elicited through abrogation of MAPK signaling; however, the drug
did not discriminate between those cells with aberrant MAPK
activity and wild-type cells (55). Tsai et al. report the discovery
of a selective inhibitor PLX4720 of BRAF V600E whose cytotoxic
effects are specific to mutant cells only (57). This PLX4720 drug
induced cell cycle arrest and apoptosis in V600E mutant cell lines
derived from colon carcinoma, and melanoma cells and yet had
minimal effects in other cancer cell lines which did not possess the
V600E mutant, including RAS-mutant colon carcinoma cells, large
cell lung cancer cells, and metastatic melanoma (57). Moreover, a
dose of 20 mg/kg PLX4720 was given orally for 14 days to mice
with colorectal carcinoma xenografts which harbored the V600E
mutation, achieving tumor regression below palpable levels in four
of nine mice (57). Solit et al. demonstrated that BRAF mutant cells,
unlike their wild-type relatives, are dependent on MEK signaling
for growth and survival and therefore BRAF V600E mutant cells
had enhanced sensitivity to MEK inhibitors compared to wild-
type BRAF cells and NRAS mutant cells (58). Furthermore, daily
treatment with the MEK inhibitor PD0325901 in BRAF V600E
mice xenografts showed complete suppression of growth, whereas
wild-type xenografts were insensitive to MEK inhibition (58).
Central nervous system cell lines and xenografts. In gliomas,
Huillard et al. report significantly increased survival in mice
transplanted with human V600E mutated astrocytoma cells when
treated with the first generation BRAF inhibitor vemurafenib
(PLX4720) (41). In these intracranial astrocytoma models, the
overall tumor size was decreased with BRAF inhibitor treatment,
whereas no response was observed when administered with the
wild-type BRAF control treatment (41). Moreover, Nicolaides et al.
demonstrated efficacy of the BRAFV600E inhibitor PLX4720 in
reducing tumor growth and increasing survival in the BRAFV600E
mouse model, whilst being ineffective in the wild-type xenograft
models (21). A MEK inhibitor AZD6244 was tested against the
pediatric pre-clinical testing in vitro panel with the highest in vitro
concentrations inhibiting growth by 50% in 5 of 23 cell lines
derived from a variety of pediatric cancers including glioblastoma,
rhabdomyosarcoma, rhabdoid tumors, Ewing’s sarcoma, neurob-
lastoma, acute lymphoblastic leukemia, acute myeloid leukemia,
anaplastic large cell lymphoma, and non-Hodgkin’s lymphoma
(59). When the MEK inhibitor AZD6244 was tested against PA
xenograft models, complete regression was observed in the BRAF
V600E mutant xenograft whereas tumor progression was observed
in wild-type BRAF xenografts (59).
See et al. further report the use of MEK inhibitors (AZD6244
or PD0325901) in NF1-deficient GBM cell lines with resultant
growth inhibition in a subset of cells (both agents) and in vivo
in nude mouse xenograft models (PD03125901) (8). This may
indicate that other tumors driven by NF1 loss, including PA asso-
ciated with neurofibromatosis, may be amenable to small molecule
inhibition of downstream targets in the MAPK pathway (8).
Paradoxical activation, whereby the BRAF inhibitor activates
the MAPK pathway, has been described in cells with wild-type
BRAF treated with a first generation BRAF inhibitor and appears
to be caused by transactivation of RAF dimers to initiate ERK
signaling (60). Moreover, Hatzivassilliou et al. have called for
careful patient selection in RAF inhibitor trials due to the find-
ing of paradoxical activation of the MAPK pathway in V600E
negative cells through RAF1 priming (61). Second generation
BRAF inhibitors, such as PLX PB3, on the other hand, have
been found to have equal action against both the mutant and
fusion protein (62). These BRAF inhibitors do not cause para-
doxical activation in cells containing wild-type BRAF resulting
in the desired effects of MAPK pathway inhibition and decreased
proliferation (62).
BRAF and MAPK inhibitors in clinical cohorts
Currently, there are few trials involving MAPK inhibiting agents
and pediatric LGGs (ongoing trials are summarized in Table 3).
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Table 3 | Small molecule inhibitors currently in clinical trials to evaluate safety and efficacy in pediatric low-grade gliomas and other tumors.
Drug Target Tumor type Phase Problems reported Reference/trial
identifier
Dabrafeniba BRAF BRAF V600E positive
tumors including HGG
and LGG
I/IIa Rash, palmar–plantar syndrome, skin
thickening, headaches, GI disturbances,
arthralgia, alopecia, fever, lethargy, squamous
cell carcinomas, photosensitivity, kidney
dysfunction, pancreatitis, and loss of fertility
NCRN511 (67, 68)
Dabrafeniba BRAF BRAF V600E positive
solid tumors
II As above NCT01677741
Trametinib (in
combination with
dabrafenib)
MEK 1/2 BRAF V600E positive
solid tumors
II No study results NCT02034110 (69)
Selumetinib
(AZD6244)a
MEK 1/2 LGG I/II No study results NCT01386450
Selumetinib
(AZD6244)a
MEK 1/2 LGG I/II No study results NCT01089101
Everolimus
(RAD001)a
mTOR NF1-recurrent or
refractory gliomas
II Myelosuppression, stomatitis, rash, fatigue,
nausea, headaches, pneumonitis, amenorrhea,
loss of fertility, fluid retention, and blood sugar
disturbances – requires monitoring (from CRUK
website,
http://www.cancerresearchuk.org/about-
cancer/cancers-in-general/treatment/cancer-
drugs/everolimus)
NCT01158651 (70)
Everolimus
(RAD001)a
mTOR Recurrent or refractory
LGG
II No study results NCT01734512
Everolimus
(RAD001)a
mTOR Recurrent or refractory
LGG
II No results NCT00782626
Sorafenib (BAY
43-9006)a
RAF kinases
(RAF1>BRAF),
VEGF, and PDGFR
Recurrent or
progressive low-grade
astrocytomas
II Raised alanine aminotransferase, raised
aspartate aminotransferase, diarrhea,
mucositis, headache, rash, dry skin,
hand–foot–skin syndrome, fatigue, alopecia,
anorexia, hypophosphatemia, and lymphopenia
NCT01338857 (71–73)
RAF kinases
(RAF1>BRAF),
VEGF, and PDGFR
Metastatic melanoma II Fatigue, pain, gastrointestinal disturbance
(diarrhea), and dermatological reactions
(palmar–plantar syndrome, rash), increased risk
of bleeding, and loss of fertility
(66)
Vemurafenib
(PLX4032/
PLX4720)a
BRAF Recurrent or refractory
BRAF V600E mutant
gliomas
0 No results NCT01748149 (74)
Vemurafenib
(PLX4032/
PLX4720)a
BRAF Metastatic melanoma II/III Arthralgia, rash, fatigue, alopecia,
keratoacanthoma, squamous cell carcinoma,
photosensitivity, nausea, and diarrhea
(75–77)
Vemurafenib/
RO5185426
(BRIM-P trial)a
BRAF Stage IIIc/IV melanoma
with BRAF V600E
mutation
I No results NCRN324
aDrugs marked are known to cross the blood–brain barrier and thus may be of use in gliomas. Information regarding trials can be found at http:// clinicaltrials.gov/
using the trial identifiers quoted. Accessed: 27/08/2014 (78).
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BRAF and MAPK inhibitors in melanoma. Much of the clini-
cal research into agents such as BRAF or MEK inhibitors has been
performed on V600E positive metastatic melanomas in adults (63–
66). Although these tumors are distinct from pediatric gliomas,
information gained on safety, toxicity, dosage, and efficacy of
these novel agents can help us understand the potential of these
new drugs in treating these LGGs arising with similar molecular
alterations (39, 43).
Bollag et al. report 26/36 metastatic melanoma patients achiev-
ing a partial or complete response to maximum tolerated dose
of vemurafenib in a phase I clinical trial (78). The main prob-
lem reported in this trial was the development of multiple skin
squamous cell carcinomas in 31% patients, a finding which has
been replicated in several other BRAF inhibitor trials (64, 75, 78).
A further phase II study in patients with metastatic melanoma
reported an overall response rate of 53% with vemurafenib, with
a median overall survival 15.9 months compared to 6–10 months
with standard therapy (77). A phase III clinical trial of vemu-
rafenib compared to the standard therapy dacarbazine in previ-
ously untreated metastatic melanoma with known BRAF V600E
mutation demonstrated an increase in overall survival of 20%,
and a reduction of 63% in the risk of death in the vemu-
rafenib group (75). Common adverse effects reported with the
BRAF inhibitor were again cutaneous squamous cell carcinoma,
as well as those detailed in Table 3. The overwhelming success
of treatment of metastatic melanoma with this novel agent led
to the decision that patients originally randomized to dacar-
bazine should be allowed to cross over into the other treatment
group (75).
BRAF and MAPK inhibitors in pediatric glioma. In pediatric
low-grade astrocytomas, a recent phase II trial of the multikinase
inhibitor sorafenib (Table 3) was discontinued early due to the
unexpected acceleration of tumor growth (73). Eleven patients
with progressive LGG following at least one chemotherapy treat-
ment were recruited, three of which were positive for NF1 and five
who possessed the BRAF gene alteration KIAA1549:BRAF (73).
The pathology included pilocytic and PMAs, DA, GG, and LGG
not otherwise specified (73). The median time to tumor progres-
sion was 2.8 months in nine patients, and after three cycles of
treatment, all but two participants had experiences disease pro-
gression (73). Sorafenib was well tolerated but the striking finding
was the rapid progression of these usually slow growing tumors
leading to the discontinuation of this trial (73).
Resistance to inhibitors
Resistance to inhibitors in melanoma. Duration of response to
BRAF inhibitors in metastatic melanoma has been recorded as
ranging from 2 to 18 months (64). Several diverse mechanisms
for this resistance have been proposed, including receptor tyrosine
kinase and NRAS upregulation (79), dimerization of wild-type or
fused BRAF (60, 62, 80), and through the other RAF kinases most
notably RAF1 (60, 61, 81–83). RAF1 mutations lead to increased
homodimerization and heterodimerization with BRAF following
exposure to the RAF inhibitor PLX4032 (82). Increased dimeriza-
tion leads to the development of resistance to PLX4032, known
clinically as vemurafenib, in A725 cells (82). Emery et al. report
novel MEK 1 mutations arising as a consequence of treatment
of metastatic melanoma with the MEK inhibitor AZD6244 (84).
MEK mutations were found either in the allosteric drug binding
site or in one of the function domains and were shown to cause
pharmacological resistance to both AZD6244 and cross resistance
to the BRAF inhibitor PLX4720 (84). Other MEK1 mutations have
been described as a mechanism conferring resistance in metastatic
melanoma from a patient with an initial near-complete response to
PLX4032 with subsequent relapse in week 16 of treatment leading
to rapid disease progression and death (85). Further mechanisms
of developing resistance have been described including increased
COT expression (a gene transcribed from MAP3K8 which acts
as a MAPK agonist) which increases phosphorylation of ERK and
MEK in a RAF-independent fashion leading to PLX4720 resistance
in metastatic melanoma cell lines (86). Furthermore, this resis-
tance extended to MEK inhibition with AZD6244 indicating that
COT may act through both MEK-dependent and -independent
mechanisms (86).
Overcoming limitations through combination therapy
Combined BRAF and MEK inhibition has been attempted as
a method of overcoming resistance (83). Combined therapy
using both a BRAF inhibitor (PLX4720) and a MEK inhibitor
(AZD6244) has demonstrated the ability to overcome resistance
to MEK inhibition in metastatic melanoma cell lines (78, 80).
Fragomeni et al. demonstrated the ability to induce complete
regression of V600E positive xenograft metastatic melanomas
through combining CRM1 and BRAF inhibition (87). CRM1 is
known to play a role in melanoma proliferation, but has not
been found to be part of tumor development or progression
in LGGs to date (87). Flexible switching between RAF isoforms
as a mechanism of resistance to RAF inhibitors may be over-
come through co-targeting of MEK and IGF1R or PI3K in BRAF
inhibitor-resistant melanoma cells (BRAF inhibitor-SB-590885)
(25). A single RAF isoform was found to be sufficient to activate
downstream signaling and knock down of two isoforms was not
sufficient to induce cell cycle arrest seen when all three isoforms
were blocked (25).
Huillard et al. demonstrated the increased efficacy of dual
therapy combining the BRAF V600E inhibitor PLX4720 and the
CDK4/6 inhibitor PD0332991 in human GBM xenograft models
compared to either agent as a monotherapy (41). Combination
of these two agents directly targeted two distinct enzymatic activ-
ities and was shown to suppress the paradoxical stimulation of
Akt (Figure 1) which occurs with treatment of xenografts with
PLX4720 alone (41).
In clinical cohorts, the timing and order of combination ther-
apy has been found to impact on outcome, with prolonged survival
being seen in patients receiving MEK inhibitors before BRAF
inhibitors compared to the reverse sequence of drug adminis-
tration (88). Moreover, there was increased tolerability of com-
bination therapies in this sequence, with a lower incidence of the
development of neoplastic cutaneous skin lesions (88). The testing
of agents in combination to overcome resistance is interesting in
the pre-clinical setting. However, at present, they cannot be con-
sidered for clinical trials in pediatric patients due to regulatory
issues.
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CONCLUSION
Currently, assessment of the KIAA1549 BRAF fusion is most use-
ful as a diagnostic biomarker in posterior fossa PAs. Although the
BRAF V600E mutation is more prevalent in PXAs, it has been
described to varying degrees in other pediatric LGGs and is of
less diagnostic use. In terms of prognosis, the KIAA1549 BRAF
fusion has been described as an independent positive prognostic
biomarker in low-grade pediatric gliomas, irrespective of tumor
type. As more targeted molecular therapies become available, there
will be increased pressure for testing for both the BRAF V600E
and the KIAA1549 BRAF fusion in order to predict treatment
options in pediatric LGGs. However, it will be important to learn
from lessons from therapeutic targeting of BRAF in metastatic
melanoma, whereby targeting one pathway may induce resistance
through upregulation of other pathways. Initial cell line work sug-
gests that a combinatorial approach may be more successful. To
date although clinical trials are underway, the benefit of targeting
BRAF in pediatric LGG is as yet unproven.
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